Evidence map›Paper›PMID 39697330›Full record

ReviewFrontiers in immunology2024

Small intestinal metastasis from primary breast cancer: a case report and review of literature.

Fengqing Shen, Songxiang Wang, Shanlu Yu, Yuancong Jiang

Abstract readCase ReportsReview
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fengqing ShenDepartment of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing, China.
Songxiang WangDepartment of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing, China.
Shanlu YuDepartment of Pathology, Shaoxing People's Hospital, Shaoxing, China.
Yuancong JiangDepartment of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small intestinal metastasis from primary breast cancer remains a rare clinical occurrence. Despite extensive research into its clinicopathological features and treatment options, the specific pathogenesis and optimal management strategies remain incompletely understood. This case report presents a patient with breast cancer that metastasized to the small intestine. The primary breast tumor was diagnosed as classic invasive lobular carcinoma. Subsequent surgical intervention successfully addressed the intestinal obstruction and confirmed the metastatic origin of the small intestinal tumor. Interestingly, the metastatic lesions exhibited features suggestive of pleomorphic lobular carcinoma. A PET-CT scan was performed to evaluate the distant metastasis status of this patient. Notably, hormonal receptor status shifted from positive to negative, while HER2 expression changed from negative to low between the primary tumor and metastatic lesions. The presence of an undiagnosed pleomorphic component in the primary tumor might explain the disease's progressive nature. In this case, systemic treatment with trastuzumab deruxtecan yielded favorable therapeutic outcomes. Overall, our findings suggest that re-evaluation of receptor status in breast cancer metastases is crucial for tailoring treatment strategies. Furthermore, a combination of palliative resection of small intestinal metastases and targeted therapy for HER2-low breast cancer may potentially improve survival.

Indexed as

Breast NeoplasmsCarcinoma, LobularErb-b2 Receptor Tyrosine KinasesFemaleHumansIntestinal NeoplasmsIntestine, SmallMiddle AgedPositron Emission Tomography Computed TomographyTrastuzumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabchemotherapyHER2 low expressionpleomorphic lobular carcinomasmall intestinal metastasissurgerytrastuzumab deruxtecan

Identifiers

PMID39697330
PMCPMC11653178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.